[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grail Inc (GRAL)

Grail Inc (GRAL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,076,290
  • Shares Outstanding, K 42,917
  • Annual Sales, $ 147,170 K
  • Annual Income, $ -408,350 K
  • EBIT $ -516 M
  • EBITDA $ -353 M
  • 60-Month Beta 3.03
  • Price/Sales 21.56
  • Price/Cash Flow N/A
  • Price/Book 1.27

Options Overview Details

View History
  • Implied Volatility 99.48% (-2.35%)
  • Historical Volatility 67.79%
  • IV Percentile 73%
  • IV Rank 68.24%
  • IV High 114.54% on 10/30/25
  • IV Low 67.09% on 09/04/25
  • Expected Move (DTE 18) 12.07 (16.84%)
  • Put/Call Vol Ratio 1.60
  • Today's Volume 738
  • Volume Avg (30-Day) 913
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 24,007
  • Open Int (30-Day) 21,557
  • Expected Range 59.61 to 83.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.88
  • Number of Estimates 3
  • High Estimate $-2.81
  • Low Estimate $-3.00
  • Prior Year $-3.18
  • Growth Rate Est. (year over year) +9.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.38 +42.28%
on 04/30/26
79.50 -9.84%
on 05/28/26
+21.99 (+44.25%)
since 04/29/26
3-Month
41.53 +72.60%
on 03/13/26
79.50 -9.84%
on 05/28/26
+18.45 (+34.66%)
since 02/27/26
52-Week
29.95 +139.33%
on 08/20/25
118.84 -39.68%
on 01/22/26
+30.59 (+74.45%)
since 05/28/25

Most Recent Stories

More News
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer

GRAL : 71.68 (-3.03%)
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round  

GRAL : 71.68 (-3.03%)
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MENLO PARK, Calif. , May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted...

GRAL : 71.68 (-3.03%)
GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

MENLO PARK, Calif. , May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...

GRAL : 71.68 (-3.03%)
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif. , May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...

GRAL : 71.68 (-3.03%)
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified...

GRAL : 71.68 (-3.03%)
GRAIL's Revenue Growth Continues, But the FDA Decision Everyone's Waiting For Remains Unresolved

Barchart Research What to Expect from GRAL Earnings GRAL Generated May 4, 2026 Current Price $55.66 EPS Estimate $$-3.00 Consensus Rating Moderate Buy Average Move 14.27% GRAIL's Revenue Growth Continues,...

GRAL : 71.68 (-3.03%)
Dear PayPal Stock Fans, Mark Your Calendars for May 5

PYPL stock has a very low valuation and multiple, powerful, potential catalysts. Here's what else to know ahead of its Q1 earnings.

PYPL : 44.75 (+0.65%)
SNDK : 1,694.98 (+3.25%)
GRAL : 71.68 (-3.03%)
HPQ : 27.04 (+8.12%)
GEV : 968.32 (-2.78%)
WMT : 115.75 (-2.65%)
GRAIL to Present at the BofA Securities 2026 Health Care Conference

MENLO PARK, Calif. , April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...

GRAL : 71.68 (-3.03%)
GRAIL to Announce First Quarter 2026 Financial Results

MENLO PARK, Calif. , April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue...

GRAL : 71.68 (-3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.

See More

Key Turning Points

3rd Resistance Point 77.62
2nd Resistance Point 76.05
1st Resistance Point 73.87
Last Price 71.68
1st Support Level 70.12
2nd Support Level 68.55
3rd Support Level 66.37

See More

52-Week High 118.84
Fibonacci 61.8% 84.88
Fibonacci 50% 74.39
Last Price 71.68
Fibonacci 38.2% 63.91
52-Week Low 29.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.